Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Can This Tiny Biotech Stock Pay Off Big for Celgene?
Can This Tiny Biotech Stock Pay Off Big for Celgene?
Celgene Corp (NASDAQ: CELG) loves cozying up to emerging biotech stocks working on next-generation medicine, and one of those collaborations is with Jounce Therapeutics (NASDAQ: JNCE). Celgene....
The 4 Largest Pure-Play Marijuana Stocks
The 4 Largest Pure-Play Marijuana Stocks
Marijuana hasn't come by the nickname "the green rush" by accident. If we take a closer look at the performance of marijuana stocks, most have had investors seeing a lot of green over the trailing....
A Big Hedge Fund Is Behind Mednax Soaring 12.7% Today
A Big Hedge Fund Is Behind Mednax Soaring 12.7% Today
Shares of Mednax (NYSE: MD) were up 12.7% at 3:30 p.m. EST Thursday after Paul Singer's Elliott Management revealed a 7% stake in the company and agreed to speak to management about ways to boost....
Here's Why Achillion Pharmaceuticals Is Soaring 19.5% Today
Here's Why Achillion Pharmaceuticals Is Soaring 19.5% Today
After Achillion Pharmaceuticals (NASDAQ: ACHN) priced its shares that Johnson & Johnson (NYSE: JNJ) is selling at $2.75 each, the company is rallying back 19.5% as of 3:15 p.m. EST.Johnson....
Genomic Health, Inc. Turns a Profit (With an Asterisk)
Genomic Health, Inc. Turns a Profit (With an Asterisk)
Genomic Health (NASDAQ: GHDX) recorded a $1.1 million profit during the third quarter, something it's been shooting for as it's improved its bottom line for each of the last nine consecutive....
Here's Why Nektar Therapeutics Is Skyrocketing 70% in November
Here's Why Nektar Therapeutics Is Skyrocketing 70% in November
After the company told investors that it plans to file for Food and Drug Administration approval for a drug that could disrupt the $12 billion market for opioid painkillers, Nektar Therapeutics....
Where Will Aurinia Pharmaceuticals Be in 5 Years?
Where Will Aurinia Pharmaceuticals Be in 5 Years?
Predicting the future isn't hard at all. Predicting the future accurately is a different matter altogether.I wanted to state that at the outset before attempting to predict how things will unfold....
5 Supernova Stocks That Have Flown Under the Radar: NuVasive
5 Supernova Stocks That Have Flown Under the Radar: NuVasive
Last week on the Rule Breaker Investing podcast, Motley Fool co-founder David Gardner reviewed the performance of two sets of his buy-and-hold stock picks: one set with a five-year horizon, and....
Is Opko Health Inc. a Buy?
Is Opko Health Inc. a Buy?
Longtime Opko Health Inc. (NASDAQ: OPK) shareholders have a lot to be upset about. Using about $1.47 billion of its own stock to acquire a big lab service provider a couple years ago was supposed....
Is Intuitive Surgical, Inc. a Buy?
Is Intuitive Surgical, Inc. a Buy?
What goes up must come down, right?That's probably been the hope for investors wanting to buy Intuitive Surgical (NASDAQ: ISRG) stock on a dip. So far this year, though, there hasn't been much of....
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
What's the best big pharma stock?Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others.....
Better Buy: Veeva Systems Inc vs. Athenahealth, Inc
Better Buy: Veeva Systems Inc vs. Athenahealth, Inc
Today's battle features a convergence of two of the most promising industries of the past decade: healthcare and software as a service (SaaS). Veeva Systems (NYSE: VEEV) offers cloud solutions for....
Here's Why Sangamo Therapeutics Rose as Much as 16.3% Today
Here's Why Sangamo Therapeutics Rose as Much as 16.3% Today
Shares of Sangamo Therapeutics (NASDAQ: SGMO) rose over 16% today after the company announced that the first patient had been dosed in a phase 1/2 trial evaluating the potential for its....
Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
Even though biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't have any drugs on the market, it had a solid third quarter in terms of pipeline development, with a drug passing its phase 3....
Here's Why Acorda Therapeutics Got Crushed Today
Here's Why Acorda Therapeutics Got Crushed Today
Shares of biopharma Acorda Therapeutics (NASDAQ: ACOR) dropped as much as 40.1% Wednesday after the company issued an update on its second-leading drug candidate. The company is increasing the....
Why Achillion Pharmaceuticals Stock Is Falling Today
Why Achillion Pharmaceuticals Stock Is Falling Today
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are falling hard today after the company announced that Johnson & Johnson (NYSE: JNJ) has decided to sell 18.4 million of the drugmaker's....
Here's What You Need to Know About Intrexon's Third-Quarter 2017 Earnings
Here's What You Need to Know About Intrexon's Third-Quarter 2017 Earnings
Shares of synthetic biology conglomerate Intrexon (NYSE: XON) were crushed following the release of third-quarter 2017 earnings last week. Although missing Wall Street's revenue expectations....

	 
Quantum Genomics announces recruitment of first patients in the NEW-HOPE arterial hypertension study in the United States
Quantum Genomics announces recruitment of first patients in the NEW-HOPE arterial hypertension study in the United States
Press Release Paris & New York, 15 November 2017 · A study to improve targeting is being carried out in the United States · NEW-HOPE: Galien MedStartUp Award-Winning Phase II Clinical....

	 
QUANTUM GENOMICS : Recrutement aux Etats-Unis des premiers patients de l'étude NEW-HOPE dans l'hypertension artérielle
QUANTUM GENOMICS : Recrutement aux Etats-Unis des premiers patients de l'étude NEW-HOPE dans l'hypertension artérielle
Communiqué de presse Paris, le 15 novembre 2017 Une étude menée aux Etats-Unis pour un meilleur ciblage NEW-HOPE : un essai clinique de phase II récompensé par le prix Galien....
Unternehmensanalyse Gilead Sciences
Unternehmensanalyse Gilead Sciences
Gilead Sciences ist ein sehr profitables Unternehmen aus der Pharma- und Biotechnik Branche. Das Unternehmen produziert dabei Medikamente und Präparate für diverse Krankheiten. Die wichtigsten....
Is Valeant Turning Things Around?
Is Valeant Turning Things Around?
Valeant Pharmaceuticals (NYSE: VRX) is notorious for its drug price gouging scandal a few years ago, an incident that caused the stock to tank and public opinion of the company plummeting to hit....
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
Donald Trump's next top pick for running the Department of Health and Human Services (HHS) is Eli Lilly & Co. (NYSE: LLY) executive Alex Azar, and that's drawing the ire of patient advocates....

	 
Medicrea participera à la conférence annuelle Piper Jaffray Healthcare
Medicrea participera à la conférence annuelle Piper Jaffray Healthcare
Medicrea participera à la 29ème conférence annuelle de Piper Jaffray Healthcare à New York Lyon et New York, 14 novembre, 2017 - Le Groupe Medicrea (Euronext Growth Paris : FR0004178572 -....
Ionis Pharmaceuticals Inc. Sets Itself Up for Growth
Ionis Pharmaceuticals Inc. Sets Itself Up for Growth
Ionis Pharmaceuticals' (NASDAQ: IONS) third-quarter earnings were a bit humdrum considering partner Biogen (NASDAQ: BIIB) spilled the beans on sales of Spinraza a few weeks ago when it reported....
Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer
Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer
Bayer AG (NASDAQOTH: BAYRY) has entered into a collaborative partnership with Loxo Oncology (NASDAQ: LOXO) that could make it a global leader in cancer drugs that are used in patients based on....